our company evolent health supports progressive health care systems lead, build and own the path to value-based care. headquartered in arlington, virginia, we are backed by: the advisory board company (nasdaq: abco), university of pittsburgh medical center health plan, and tpg growth. we integrate the people, processes and technology needed to advance value-based care delivery and innovative payment models. our culture we’ve built a team of dedicated individuals who genuinely enjoy working together. our accessible leadership team cultivates an open-door environment. we take smart risks and when we fail, we fail forward. we respect and encourage commitments outside of work. while we don’t all work the same way or the same hours, we are all dedicated to exceptional results. our benefits treadmill desks, healthy snacks and wellness challenges are just part of our resolve to promote a healthy (and fun!) work environment. we recognize and reward our most valuable asset—our team—wi
Company profile
Ticker
EVH
Exchange
Website
CEO
Frank Williams
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Evolent Health LLC • Evolent Specialty Services, Inc. • Evolent Assurance Solutions, LLC • EH Holding Company, Inc. • Justify Holdings, Inc. • Evolent Health International Private Ltd. • Evolent Care Partners Holding Company, Inc. • Evolent Care Partners of Texas, Inc. • The Accountable Care Organization Ltd. • Evolent Care Partners of North Carolina, Inc. ...
EVH stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
23 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Evolent Announces Fourth Quarter and Full Year 2023 Results
22 Feb 24
8-K
Evolent Adds Russell Glass, Headspace CEO, to Board of Directors
14 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Dec 23
8-K
Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan
6 Dec 23
8-K
Evolent Health, Inc. Announces Proposed Offering of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan
5 Dec 23
8-K
Other Events
3 Nov 23
424B7
Prospectus with selling stockholder info
3 Nov 23
Transcripts
EVH
Earnings call transcript
2023 Q3
2 Nov 23
EVH
Earnings call transcript
2023 Q2
2 Aug 23
EVH
Earnings call transcript
2023 Q1
3 May 23
EVH
Earnings call transcript
2022 Q4
22 Feb 23
EVH
Earnings call transcript
2022 Q3
2 Nov 22
EVH
Earnings call transcript
2022 Q2
3 Aug 22
EVH
Earnings call transcript
2022 Q1
5 May 22
EVH
Earnings call transcript
2021 Q4
24 Feb 22
EVH
Earnings call transcript
2021 Q3
4 Nov 21
EVH
Earnings call transcript
2021 Q2
5 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 224.50 mm | 224.50 mm | 224.50 mm | 224.50 mm | 224.50 mm | 224.50 mm |
Cash burn (monthly) | (no burn) | (no burn) | 10.29 mm | 13.71 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 61.49 mm | 81.93 mm | n/a | n/a |
Cash remaining | n/a | n/a | 163.01 mm | 142.57 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 15.8 | 10.4 | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 203 |
Opened positions | 19 |
Closed positions | 32 |
Increased positions | 82 |
Reduced positions | 71 |
13F shares | Current |
---|---|
Total value | 3.31 tn |
Total shares | 131.32 mm |
Total puts | 185.10 k |
Total calls | 51.30 k |
Total put/call ratio | 3.6 |
Largest owners | Shares | Value |
---|---|---|
FMR | 16.50 mm | $464.29 bn |
Vanguard | 10.59 mm | $288.49 bn |
Engaged Capital I | 7.89 mm | $239.72 mm |
BLK Blackrock | 7.84 mm | $213.45 bn |
JPM JPMorgan Chase & Co. | 6.05 mm | $164.70 bn |
Wellington Management | 4.24 mm | $115.43 bn |
Rock Springs Capital Management | 3.87 mm | $105.24 bn |
BLVGF Bellevue | 3.68 mm | $100.13 bn |
Granahan Investment Management | 2.95 mm | $80.44 bn |
Orbimed Advisors | 2.90 mm | $78.85 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Mar 24 | Daniel Joseph McCarthy | Class A Common Stock | Payment of exercise | Dispose F | No | No | 34.41 | 5,638 | 194.00 k | 217,952 |
2 Mar 24 | Jonathan Weinberg | Class A Common Stock | Payment of exercise | Dispose F | No | No | 34.41 | 4,830 | 166.20 k | 167,027 |
1 Mar 24 | Aammaad Shams | Class A Common Stock | Payment of exercise | Dispose F | No | No | 34.41 | 2,569 | 88.40 k | 54,946 |
1 Mar 24 | Aammaad Shams | Class A Common Stock | Grant | Acquire A | No | No | 0 | 7,491 | 0.00 | 57,515 |
1 Mar 24 | Daniel Joseph McCarthy | Class A Common Stock | Payment of exercise | Dispose F | No | No | 34.41 | 13,210 | 454.56 k | 223,590 |
1 Mar 24 | Daniel Joseph McCarthy | Class A Common Stock | Grant | Acquire A | No | No | 0 | 19,398 | 0.00 | 236,800 |
1 Mar 24 | Russell Monroe Glass | Class A Common Stock | Grant | Acquire A | No | No | 0 | 1,163 | 0.00 | 1,163 |
1 Mar 24 | Emily Ann Rafferty | Class A Common Stock | Payment of exercise | Dispose F | No | No | 34.41 | 7,049 | 242.56 k | 72,269 |
1 Mar 24 | Emily Ann Rafferty | Class A Common Stock | Grant | Acquire A | No | No | 0 | 10,911 | 0.00 | 79,318 |
1 Mar 24 | Jonathan Weinberg | Class A Common Stock | Payment of exercise | Dispose F | No | No | 34.41 | 7,460 | 256.70 k | 171,857 |
News
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $44
28 Mar 24
Navigating 4 Analyst Ratings For Evolent Health
15 Mar 24
JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $52
15 Mar 24
Oppenheimer Initiates Coverage On Evolent Health with Outperform Rating, Announces Price Target of $45
1 Mar 24
These Analysts Revise Their Forecasts On Evolent Health After Upbeat Results
23 Feb 24